

Induced Pluripotent Stem Cells Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Process (Manual iPSC Production Process, Automated iPSC Production Process), By Product (Instruments/ Devices, Automated Platforms, Consumables & Kits, Services), By Application (Drug Development and Discovery, Regenerative Medicine, Toxicology Studies, Others), By End-user (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics) By Region and Competition

Market Report | 2023-10-03 | 178 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4900.00
- Multi-User License \$5900.00
- Custom Research License \$8900.00

Report description:

Global Induced Pluripotent Stem Cells Production Market has valued at USD 1.24 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 10.14% through 2028. Induced pluripotent stem cells (iPSCs) represent a groundbreaking advancement in regenerative medicine. These cells have the potential to transform the treatment landscape for a wide range of diseases and conditions, from neurodegenerative disorders to cardiovascular diseases. As the iPSC technology continues to evolve, so does the market for their production. Induced pluripotent stem cells are derived from adult cells, such as skin cells or blood cells, that have been reprogrammed to exhibit embryonic stem cell-like properties. These cells can self-renew indefinitely and differentiate into various cell types, making them a valuable resource for regenerative medicine and drug discovery. iPSCs offer numerous advantages over traditional embryonic stem cells, including ethical considerations and reduced risk of immune rejection when used in therapeutic applications.

The iPSC production market has been steadily growing over the past decade, driven by increasing research and development activities in the field of regenerative medicine and drug discovery. The ability to generate patient-specific iPSCs holds immense

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

potential for developing personalized therapies. This approach has gained traction, particularly in the treatment of genetic disorders. Governments, private institutions, and pharmaceutical companies continue to invest heavily in iPSC research. This financial support fuels advancements in technology and accelerates market growth. iPSCs are increasingly used in drug discovery to model diseases and screen potential drug candidates. Their application in toxicity testing offers a cost-effective and efficient alternative to animal testing. iPSCs are being explored as potential treatments for a wide range of diseases, including Parkinson's disease, Alzheimer's disease, heart diseases, and diabetes. These applications contribute to the market's expansion.

Key Market Drivers

Expanding Therapeutic Applications

The therapeutic potential of iPSCs continues to broaden. These cells are being explored as candidates for treating a wide range of diseases, including neurodegenerative disorders like Parkinson's and Alzheimer's, heart diseases, diabetes, and more. With each new therapeutic application, the market for iPSC production expands. Patients and healthcare providers are eager for innovative treatment options, further driving the demand for iPSCs. iPSCs, which can be derived from adult cells and then coaxed into becoming various cell types, have proven to be an invaluable resource in the quest for innovative therapeutic solutions. One of the most promising areas of iPSC research is in the treatment of neurodegenerative diseases like Parkinson's and Alzheimer's. iPSCs can be transformed into dopaminergic neurons, allowing researchers to study disease mechanisms, screen potential drug candidates, and even develop cell-based therapies for these devastating conditions. iPSCs are being used to generate cardiac cells, enabling the modeling of heart diseases and the testing of new drugs for safety and efficacy. Additionally, there is ongoing research into using iPSC-derived cardiac cells for regenerative treatments after heart attacks and other cardiac injuries. The potential to differentiate iPSCs into insulin-producing pancreatic beta cells holds immense promise for diabetes treatment. Researchers are working to create functional beta cells for transplantation, offering the hope of a cure for type 1 diabetes and improved management options for type 2 diabetes. iPSCs offer a path towards personalized therapies for patients with genetic disorders. By generating iPSCs from patients with specific genetic mutations and then correcting those mutations, researchers can develop patient-specific, genetically corrected cells for transplantation or disease modeling.

The expanding therapeutic applications of iPSCs are revolutionizing the way we approach disease treatment and prevention. They offer personalized solutions, improved disease modeling, and a bridge to regenerative medicine that was once considered science fiction. As these applications advance, they drive the demand for iPSC production, spurring innovation and investment in the field. Moreover, the potential cost savings associated with iPSC-based therapies, such as reduced hospitalization, fewer complications, and improved outcomes, make them an attractive option for healthcare providers and payers. This further incentivizes the growth of the iPSCs production market, as companies and researchers strive to meet the increasing demand for iPSCs and their derivatives.

Drug Discovery and Toxicity Testing

iPSCs have become invaluable tools in the pharmaceutical industry. They are used to model diseases, screen potential drug candidates, and assess drug toxicity. Compared to traditional methods, iPSC-based assays offer greater accuracy and efficiency, reducing costs and time in the drug development process. As the demand for more efficient drug discovery and safety testing methods grows, so does the demand for iPSCs in production. The induced pluripotent stem cells (iPSCs) production market has experienced remarkable growth, thanks in large part to its pivotal role in drug discovery and toxicity testing. These versatile cells have revolutionized the pharmaceutical industry by providing a highly efficient and ethical platform for evaluating drug candidates, understanding disease mechanisms, and ensuring the safety of novel compounds. As a result, iPSC-based disease models have become indispensable in drug discovery. Traditional drug discovery involves extensive testing in animal models, which can be costly, time-consuming, and ethically challenging. iPSCs offer an alternative approach by allowing researchers to assess the efficacy and safety of drug candidates early in the development process. iPSC-derived cells can be used in high-throughput screening assays to quickly identify promising compounds and eliminate ineffective or toxic ones. Patient-Specific Drug Testing: iPSCs can be generated from patients with specific diseases, creating a patient-specific platform for drug testing. This approach enables personalized medicine by tailoring treatment strategies to individual patients. Induced pluripotent stem cells are a type of stem cell that can be generated from adult cells, such as skin cells or blood cells, by reprogramming them to a pluripotent state, similar to embryonic stem cells. This breakthrough technology, first pioneered by Shinya Yamanaka in 2006, has opened up a world of possibilities in regenerative medicine, disease modeling, and drug discovery. One of the most remarkable

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

applications of iPSCs is their potential to create patient-specific disease models and enable personalized medicine. These iPSC-derived cells can then be used to screen potential drug candidates, assess their efficacy, and better understand disease mechanisms.

Technological Advancements

Advancements in iPSC production techniques have made the process more efficient and cost-effective. Automation, genome editing technologies like CRISPR-Cas9, and optimized culture conditions have all contributed to the streamlining of iPSC production. These technological innovations not only make iPSCs more accessible to researchers but also enable their use in larger-scale applications, such as cell-based therapies. One of the key breakthroughs has been the development of more efficient and less invasive reprogramming methods. Initially, the process of reprogramming involved the use of viral vectors, which carried the risk of integrating foreign genetic material into the host genome. However, advances in non-integrating reprogramming techniques, such as mRNA and episomal vectors, have mitigated these concerns, making iPSC generation safer and more clinically relevant. Furthermore, the field has witnessed substantial progress in the automation and scaling up of iPSC production. Automated systems equipped with robotics and advanced software have streamlined the generation, maintenance, and differentiation of iPSCs, significantly reducing the time and labor required for these processes. This increased efficiency has not only accelerated research efforts but also lowered production costs, making iPSC technology more accessible to researchers and industry players alike. Another game-changing technological advancement is the development of 3D cell culture systems and bioprinting techniques. Traditional 2D cell culture models have limitations when it comes to replicating the complex three-dimensional environments of human tissues. 3D cell cultures, on the other hand, offer a more physiologically relevant platform for iPSC differentiation and tissue engineering. Advanced bioprinting technologies enable the precise placement of iPSC-derived cells and biomaterials, allowing for the creation of intricate tissue structures. This has profound implications for drug screening, disease modeling, and eventually, the transplantation of lab-grown organs and tissues. Moreover, the regulatory landscape surrounding iPSCs has evolved to ensure their safety and efficacy. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) have been actively engaged in establishing guidelines and standards for iPSC-based therapies.

Increasing Awareness and Acceptance

As awareness of iPSCs and their potential benefits spreads, their acceptance in the medical and research communities continues to grow. Researchers, clinicians, and pharmaceutical professionals are increasingly incorporating iPSCs into their work, contributing to market expansion. Additionally, patient advocacy groups and educational initiatives play a role in disseminating knowledge about iPSCs and their applications, eliminating the risk of rejection and immune response associated with other stem cell therapies. This revolutionary concept has the potential to change the landscape of medicine, offering tailored treatments that are safer and more effective. Yet, despite their immense potential, iPSCs faced several barriers, including ethical concerns, limited funding, and a lack of public awareness. One of the most significant drivers behind the increased awareness and acceptance of iPSCs is the extensive research conducted in this field. Scientists and researchers worldwide have been diligently working to unravel the potential of iPSCs in treating a plethora of diseases, including neurodegenerative disorders, cardiovascular diseases, and diabetes. These efforts have resulted in a growing body of evidence supporting the safety and efficacy of iPSC-based therapies. In addition to scientific research, prominent figures in the medical and celebrity communities have played a crucial role in raising awareness about iPSCs. Notable personalities like Michael J. Fox, who suffers from Parkinson's disease, have publicly endorsed iPSC research and its potential to find cures for debilitating diseases. Their advocacy has garnered significant media attention, thereby increasing public awareness and support for iPSC-based therapies. Furthermore, the role of patient advocacy groups cannot be understated in promoting the acceptance of iPSCs. These groups, composed of individuals and families affected by various diseases, have been instrumental in pushing for research and funding in the field of iPSCs. Their tireless efforts have led to increased government and private sector investments in iPSC research, further accelerating its development and application in clinical settings. Another essential factor contributing to the growth of the iPSCs production market is the collaboration between academia and industry. Pharmaceutical companies and biotechnology firms have recognized the immense potential of iPSCs and have entered into partnerships with research institutions to expedite their development and commercialization. These collaborations have not only infused capital into the field but have also provided the necessary expertise and infrastructure to scale up iPSC production.

Key Market Challenges

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cost of Production

One of the primary challenges facing the iPSCs production market is the high cost associated with generating and maintaining iPSCs. The complex and resource-intensive process of reprogramming adult cells into iPSCs requires specialized equipment, skilled personnel, and expensive culture media. These costs are a significant barrier for researchers and companies looking to scale up iPSC production for clinical applications. As a result, the overall cost of iPSC-based therapies remains prohibitively high, limiting their accessibility to a broader patient population. Generating iPSCs demands state-of-the-art laboratories, specialized equipment, and highly trained personnel. The need for advanced cell culture facilities with strict environmental controls adds substantially to the overall cost. Researchers and companies must invest heavily in infrastructure to create and maintain optimal conditions for iPSC cultivation. The culture media and reagents required for iPSC production are often expensive and must meet stringent quality standards. These materials are essential for maintaining cell viability, growth, and differentiation. Ensuring the consistency and quality of these components adds a significant financial burden to iPSC production.

Quality Control and Standardization

Ensuring the quality and consistency of iPSCs is essential for their safe and effective use in clinical settings. However, maintaining consistent quality across iPSC lines can be challenging due to variations in cell culture conditions, reprogramming techniques, and genetic backgrounds of donor cells. Standardization of iPSC production processes and rigorous quality control measures are necessary to address this challenge. Without a standardized approach, it becomes difficult to compare results across studies and establish a solid regulatory framework, hampering the growth of the iPSC production market.

Competition from Alternative Therapies

Pharmaceutical dissolution testing generates vast amounts of data, and effectively managing and analyzing this data is a significant challenge. Laboratories must invest in robust data management systems to store, retrieve, and interpret test results accurately. Furthermore, data integrity and traceability are crucial in pharmaceutical testing, as any errors or inconsistencies can have severe consequences. Additionally, the interpretation of dissolution test results requires expertise and a deep understanding of pharmaceutical science. Laboratories must employ skilled scientists and analysts who can translate raw data into meaningful insights for drug manufacturers. The shortage of trained professionals in this field adds to the challenges faced by the Induced Pluripotent Stem Cells Production market.

Key Market Trends

Growing Applications in Disease Modeling and Drug Development

One of the primary drivers of the iPSC production market is the expanding range of applications in disease modeling and drug development. iPSCs can be derived from patients with specific genetic mutations, allowing researchers to create disease-specific cell lines. This enables the development of more accurate and relevant disease models for studying diseases like Parkinson's, Alzheimer's, and genetic disorders. Pharmaceutical companies are increasingly using iPSCs to screen potential drug candidates, reducing the cost and time associated with traditional drug development processes. As the need for personalized medicine grows, so does the demand for iPSCs in disease modeling and drug testing.

Technological Advancements in Reprogramming Techniques

Efficient reprogramming techniques are vital for the widespread adoption of iPSCs. Over the years, significant advancements have been made in this area, making it easier and more cost-effective to generate iPSCs. The development of non-integrating reprogramming methods, such as Sendai virus and synthetic mRNA-based approaches, has eliminated concerns about genomic integration and increased the safety of iPSC generation. Furthermore, the optimization of small molecules and growth factors used in the reprogramming process has enhanced the efficiency and speed of iPSC production, making it more accessible to researchers and clinicians. The shift from traditional 2D cell culture to 3D cell culture and organoid technologies is another trend shaping the iPSC production market. 3D cultures and organoids better mimic the complex tissue architecture and microenvironment found in the human body, making them valuable tools for disease modeling, drug testing, and regenerative medicine. iPSCs play a crucial role in the development of these models, as they can be differentiated into various cell types and organized into 3D structures that closely resemble human tissues and organs.

Segmental Insights

Product Insights

Based on the products, the consumables and kits segment emerged as the dominant player in the global market for Induced

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Pluripotent Stem Cells Production in 2022. this remarkable growth can be attributed to increased demand for ipsc research, technological advancements, and standardization and quality control, etc. advancements in iPSC technology have necessitated the development of specialized consumables and kits. These innovations have made it easier for researchers to work with iPSCs, driving up the demand for high-quality reagents and materials. For instance, the development of feeder-free culture systems and xeno-free culture media has boosted the adoption of iPSCs, further fueling the consumables and kits segment.

Application Insights

Based on the Application, drug development and discovery segment emerged as the dominant player in the global market for Induced Pluripotent Stem Cells Production in 2022. This is due to the increasing importance of induced pluripotent stem cells (iPSCs) in the field of drug development and discovery. iPSCs are a type of stem cell that can be generated from adult cells and reprogrammed to become pluripotent, meaning they can differentiate into various cell types in the body.

Regional Insights

North America emerged as the dominant player in the global Induced Pluripotent Stem Cells Production market in 2022, holding the largest market share. This is on account of its advanced healthcare infrastructure, strong adoption of technology, and robust research and development activities. North America, particularly the United States, is home to state-of-the-art pharmaceutical research and testing facilities. The availability of advanced dissolution testing equipment and technology in the region ensures precision, accuracy, and efficiency in testing services.

Key Market Players

Lonza Group

Axol Biosciences Ltd.

Evotec Se

Hitachi Ltd.

Reprocells Inc.

Fate Therapeutics.

Thermo Fisher Scientific, Inc.

Merck Kgaa

Stemcellsfactory lii

Applied Stemcells Inc.

Report Scope:

In this report, the Global Induced Pluripotent Stem Cells Production Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

?[] Induced Pluripotent Stem Cells Production Market, By Process:

o[] Manual iPSC Production Process

o[] Automated iPSC Production Process

?[] Induced Pluripotent Stem Cells Production Market, By Product:

o[] Instruments/ Devices

o[] Automated Platforms

o[] Consumables & Kits

o[] Services

?[] Induced Pluripotent Stem Cells Production Market, By End-user:

o[] Research & Academic Institutes

o[] Biotechnology & Pharmaceutical Companies

o[] Hospitals & Clinics

?[] Induced Pluripotent Stem Cells Production Market, By Application:

o[] Drug Development and Discovery

o[] Regenerative Medicine

o[] Toxicology Studies

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

o Others

? Induced Pluripotent Stem Cells Production Market, By Region:

o North America

? United States

? Canada

? Mexico

o Europe

? France

? United Kingdom

? Italy

? Germany

? Spain

o Asia-Pacific

? China

? India

? Japan

? Australia

? South Korea

o South America

? Brazil

? Argentina

? Colombia

o Middle East & Africa

? South Africa

? Saudi Arabia

? UAE

? Kuwait

? Turkey

? Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Induced Pluripotent Stem Cells Production Market.

Available Customizations:

Global Induced Pluripotent Stem Cells Production market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

? Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.2.□Baseline Methodology
- 2.3.□Key Industry Partners
- 2.4.□Major Association and Secondary Sources
- 2.5.□Forecasting Methodology
- 2.6.□Data Triangulation & Validation
- 2.7.□Assumptions and Limitations
- 3.□Executive Summary
 - 3.1.□Overview of the Market
 - 3.2.□Overview of Key Market Segmentations
 - 3.3.□Overview of Key Market Players
 - 3.4.□Overview of Key Regions/Countries
 - 3.5.□Overview of Market Drivers, Challenges, Trends
- 4.□Voice of Customer
- 5.□Global Induced Pluripotent Stem Cells Production Market Outlook
 - 5.1.□Market Size & Forecast
 - 5.1.1.□By Value
 - 5.2.□Market Share & Forecast
 - 5.2.1.□By Process (Manual iPSC Production Process, Automated iPSC Production Process)
 - 5.2.2.□By Product (Instruments/ Devices, Automated Platforms, Consumables & Kits, Services)
 - 5.2.3.□By Application (Drug Development and Discovery, Regenerative Medicine, Toxicology Studies, Others)
 - 5.2.4.□By End-user (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics)
 - 5.2.5.□ By Company (2022)
 - 5.2.6.□By Region
 - 5.3.□Market Map
- 6.□North America Induced Pluripotent Stem Cells Production Market Outlook
 - 6.1.□Market Size & Forecast□
 - 6.1.1.□By Value
 - 6.2.□Market Share & Forecast
 - 6.2.1.□By Process
 - 6.2.2.□By Product
 - 6.2.3.□By End-user
 - 6.2.4.□By Application
 - 6.2.5.□By Country
 - 6.3.□North America: Country Analysis
 - 6.3.1.□United States Induced Pluripotent Stem Cells Production Market Outlook
 - 6.3.1.1.□Market Size & Forecast
 - 6.3.1.1.1.□By Value
 - 6.3.1.2.□Market Share & Forecast
 - 6.3.1.2.1.□By Process
 - 6.3.1.2.2.□By Product
 - 6.3.1.2.3.□By End-user
 - 6.3.1.2.4.□By Application
 - 6.3.2.□Mexico Induced Pluripotent Stem Cells Production Market Outlook
 - 6.3.2.1.□Market Size & Forecast
 - 6.3.2.1.1.□By Value
 - 6.3.2.2.□Market Share & Forecast
 - 6.3.2.2.1.□By Process

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3.2.2.2. By Product
- 6.3.2.2.3. By End-user
- 6.3.2.2.4. By Application
- 6.3.3. Canada Induced Pluripotent Stem Cells Production Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Process
 - 6.3.3.2.2. By Product
 - 6.3.3.2.3. By End-user
 - 6.3.3.2.4. By Application
- 7. Europe Induced Pluripotent Stem Cells Production Market Outlook
 - 7.1. Market Size & Forecast
 - 7.1.1. By Value
 - 7.2. Market Share & Forecast
 - 7.2.1. By Process
 - 7.2.2. By Product
 - 7.2.3. By End-user
 - 7.2.4. By Application
 - 7.2.5. By Country
 - 7.3. Europe: Country Analysis
 - 7.3.1. France Induced Pluripotent Stem Cells Production Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Process
 - 7.3.1.2.2. By Product
 - 7.3.1.2.3. By End-user
 - 7.3.1.2.4. By Application
 - 7.3.2. Germany Induced Pluripotent Stem Cells Production Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Process
 - 7.3.2.2.2. By Product
 - 7.3.2.2.3. By End-user
 - 7.3.2.2.4. By Application
 - 7.3.3. United Kingdom Induced Pluripotent Stem Cells Production Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Process
 - 7.3.3.2.2. By Product
 - 7.3.3.2.3. By End-user
 - 7.3.3.2.4. By Application
 - 7.3.4. Italy Induced Pluripotent Stem Cells Production Market Outlook
 - 7.3.4.1. Market Size & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Process
 - 7.3.4.2.2. By Product
 - 7.3.4.2.3. By End-user
 - 7.3.4.2.4. By Application
- 7.3.5. Spain Induced Pluripotent Stem Cells Production Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Process
 - 7.3.5.2.2. By Product
 - 7.3.5.2.3. By End-user
 - 7.3.5.2.4. By Application
- 8. Asia-Pacific Induced Pluripotent Stem Cells Production Market Outlook
 - 8.1. Market Size & Forecast
 - 8.1.1. By Value
 - 8.2. Market Share & Forecast
 - 8.2.1. By Process
 - 8.2.2. By Product
 - 8.2.3. By End-user
 - 8.2.4. By Application
 - 8.2.5. By Country
 - 8.3. Asia-Pacific: Country Analysis
 - 8.3.1. China Induced Pluripotent Stem Cells Production Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Process
 - 8.3.1.2.2. By Product
 - 8.3.1.2.3. By End-user
 - 8.3.1.2.4. By Application
 - 8.3.2. India Induced Pluripotent Stem Cells Production Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Process
 - 8.3.2.2.2. By Product
 - 8.3.2.2.3. By End-user
 - 8.3.2.2.4. By Application
 - 8.3.3. South Korea Induced Pluripotent Stem Cells Production Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Process
 - 8.3.3.2.2. By Product
 - 8.3.3.2.3. By End-user

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.3.2.4.□By Application
- 8.3.4.□Japan Induced Pluripotent Stem Cells Production Market Outlook
 - 8.3.4.1.□Market Size & Forecast
 - 8.3.4.1.1.□By Value
 - 8.3.4.2.□Market Share & Forecast
 - 8.3.4.2.1.□By Process
 - 8.3.4.2.2.□By Product
 - 8.3.4.2.3.□By End-user
 - 8.3.4.2.4.□By Application
- 8.3.5.□Australia Induced Pluripotent Stem Cells Production Market Outlook
 - 8.3.5.1.□Market Size & Forecast
 - 8.3.5.1.1.□By Value
 - 8.3.5.2.□Market Share & Forecast
 - 8.3.5.2.1.□By Process
 - 8.3.5.2.2.□By Product
 - 8.3.5.2.3.□By End-user
 - 8.3.5.2.4.□By Application
- 9.□South America Induced Pluripotent Stem Cells Production Market Outlook
 - 9.1.□Market Size & Forecast□
 - 9.1.1.□By Value
 - 9.2.□Market Share & Forecast
 - 9.2.1.□By Process
 - 9.2.2.□By Product
 - 9.2.3.□By End-user
 - 9.2.4.□By Application
 - 9.2.5.□By Country
 - 9.3.□South America: Country Analysis
 - 9.3.1.□Brazil Induced Pluripotent Stem Cells Production Market Outlook
 - 9.3.1.1.□Market Size & Forecast
 - 9.3.1.1.1.□By Value
 - 9.3.1.2.□Market Share & Forecast
 - 9.3.1.2.1.□By Process
 - 9.3.1.2.2.□By Product
 - 9.3.1.2.3.□By End-user
 - 9.3.1.2.4.□By Application
 - 9.3.2.□Argentina Induced Pluripotent Stem Cells Production Market Outlook
 - 9.3.2.1.□Market Size & Forecast
 - 9.3.2.1.1.□By Value
 - 9.3.2.2.□Market Share & Forecast
 - 9.3.2.2.1.□By Process
 - 9.3.2.2.2.□By Product
 - 9.3.2.2.3.□By End-user
 - 9.3.2.2.4.□By Application
 - 9.3.3.□Colombia Induced Pluripotent Stem Cells Production Market Outlook
 - 9.3.3.1.□Market Size & Forecast
 - 9.3.3.1.1.□By Value
 - 9.3.3.2.□Market Share & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3.3.2.1. By Process
- 9.3.3.2.2. By Product
- 9.3.3.2.3. By End-user
- 9.3.3.2.4. By Application
- 10. Middle East and Africa Induced Pluripotent Stem Cells Production Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Process
- 10.2.2. By Product
- 10.2.3. By End-user
- 10.2.4. By Application
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Induced Pluripotent Stem Cells Production Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Process
- 10.3.1.2.2. By Product
- 10.3.1.2.3. By End-user
- 10.3.1.2.4. By Application
- 10.3.2. Saudi Arabia Induced Pluripotent Stem Cells Production Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Process
- 10.3.2.2.2. By Product
- 10.3.2.2.3. By End-user
- 10.3.2.2.4. By Application
- 10.3.3. UAE Induced Pluripotent Stem Cells Production Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Process
- 10.3.3.2.2. By Product
- 10.3.3.2.3. By End-user
- 10.3.3.2.4. By Application
- 11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
- 12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
- 13. PESTLE Analysis
- 14. Porter's Five Forces Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.1.□Competition in the Industry
- 14.2.□Potential of New Entrants
- 14.3.□Power of Suppliers
- 14.4.□Power of Customers
- 14.5.□Threat of Substitute Product
- 15.□Competitive Landscape
- 15.1.□Business Overview
- 15.2.□Company Snapshot
- 15.3.□Product & Process
- 15.4.□Financials (In case of listed companies)
- 15.5.□Recent Developments
- 15.6.□SWOT Analysis
- 15.6.1.□Lonza
- 15.6.2.□Axol Biosciences Ltd.
- 15.6.3.□Evotec Se
- 15.6.4.□Hitachi Ltd.
- 15.6.5.□Reprocells Inc.
- 15.6.6.□Fate Therapeutics.
- 15.6.7.□Thermo Fisher Scientific, Inc.
- 15.6.8.□Merck Kgaa
- 15.6.9.□Stemcellsfactory Iii
- 15.6.10.□Applied Stemcells Inc.
- 16.□Strategic Recommendations

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Induced Pluripotent Stem Cells Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Process (Manual iPSC Production Process, Automated iPSC Production Process), By Product (Instruments/ Devices, Automated Platforms, Consumables & Kits, Services), By Application (Drug Development and Discovery, Regenerative Medicine, Toxicology Studies, Others), By End-user (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics) By Region and Competition

Market Report | 2023-10-03 | 178 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4900.00
	Multi-User License	\$5900.00
	Custom Research License	\$8900.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*

Phone*

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-03"/>
		Signature	<input type="text"/>